multiomics

Multimodal approaches could help drug developers connect disease biology with clinical outcomes and better understand why treatments succeed or fail. 

The expanded service brings 10x Genomics-powered single-cell RNA sequencing to Novogene Europe's Cambridge Omics Centre, providing UK researchers with local access to end-to-end workflows and bioinformatics support.

The new service adds metabolite profiling to Novogene Europe's genomics and transcriptomics capabilities, supporting integrated multiomics research.

From fleet-level monitoring to faster quantitative workflows, new expectations are emerging for how mass spectrometry platforms support decision-making at scale.

Sapient’s new mass spectrometry platform combines four workflows to map surface targets, signaling, immune activity and resistance mechanisms in tumor samples.

Harnessing multi-omics and AI, researchers are transforming drug discovery by revealing disease mechanisms, pinpointing therapeutic targets, and speeding up development.

Bristol Myers Squibb has initiated a phase 1 study of BMS-986506, a cereblon E3 ligase modulator jointly developed with Evotec, triggering a $10 million milestone.

Multi-omics analysis reveals a nine-gene signature linked to treatment failure in aggressive tumor behavior. 

Transcriptomics, proteomics, and functional genomics are converging to create a new era of mechanism-aware drug discovery. 

From multiomic diagnostics to quantum computing, leading experts share the untapped opportunities that could reshape the future of therapeutics.